 |
인쇄하기
취소
|
KFDA unveils drug re-evaluation results
The Korea Food and Drug Administration announced on March 26 that it will retract its approval for problematic 14 generic drugs in terms of bioequivalence, banning pharmaceutical companies from manufacturing and selling them.
These drugs included simvastatin generics manufactured by Kwangdong Pharm, Daewoong Pharm, Whain Pharm and Hyundai Pharm as well as other treatments made by Ilyang Phar...
These drugs included simvastatin generics manufactured by Kwangdong Pharm, Daewoong Pharm, Whain Pharm and Hyundai Pharm as well as other treatments made by Ilyang Phar...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.